Fibromyalgia Treatment Market Size & Share, by Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants); Type (Symptomatic Treatment, Targeted Treatment); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4467
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Companies Dominating the Fibromyalgia Treatment Landscape

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AbbVie Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    •  Aptinyx Inc.
    • Tonix Pharmaceuticals Holding Corp.
    • Virios Therapeutics

Browse Key Market Insights with Data Illustration:


In The News

  • Aptinyx Inc. declared the completion of the enrolment of 305 patients in the current Phase 2b study of NYX-2925 in fibromyalgia. NYX-2925 is being studied in 305 patients with fibromyalgia in a randomized, double-blind, placebo-controlled Phase 2 study.

  • Astellas Pharma Inc. has acquired bioelectronics start-up company Iota Biosciences, Inc. Astellas' Rx+ projects are estimated to accelerate in light of this acquisition.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4467
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Worldwide growing incidences of road accidents, surge in post-traumatic stress disorder (PTSD), and worldwide boost in geriatric population are some major factors driving the growth of the market.

The market is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2033.

Side effects associated with the use of fibromyalgia drugs, high adoption of generic drugs, and stringent regulations of government are estimated to hamper the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Aptinyx Inc., Tonix Pharmaceuticals Holding Corp., Virios Therapeutics, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, type, distribution channel, and by region.

The antiepileptic segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying